Evofem Biosciences, Inc. has announced the termination of its License and Supply Agreement with Windtree Therapeutics, effective March 13, 2026. This decision follows previous disclosures regarding the agreement, which was initially established on March 20, 2025, and amended shortly thereafter. The termination was mutually agreed upon by both parties, and notably, there are no fees associated with this termination. The agreement was intended for Windtree to manufacture and supply PHEXXI, a product developed by Evofem. The termination of this agreement may impact Evofem's operational execution and strategy outlook, as it seeks alternative manufacturing solutions for its products. The company has indicated that certain provisions of the agreement will remain in effect despite the termination. This development is expected to have a small negative effect on Evofem's stock price as it navigates the implications of this decision.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.